Immunome, Inc. (IMNM)
| Market Cap | 1.98B +59.3% |
| Revenue (ttm) | n/a -23.2% |
| Net Income | -254.32M |
| EPS | -2.49 |
| Shares Out | 113.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,621,275 |
| Open | 17.31 |
| Previous Close | 17.20 |
| Day's Range | 17.08 - 17.61 |
| 52-Week Range | 13.94 - 30.06 |
| Beta | 2.55 |
| Analysts | Strong Buy |
| Price Target | 35.20 (+102.3%) |
| Est. Earnings | Nov 5, 2026 |
About IMNM
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including I... [Read more]
Financial Performance
In 2025, Immunome's revenue was $6.94 million, a decrease of -23.23% compared to the previous year's $9.04 million. Losses were -$212.39 million, -27.50% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price target is $35.2, which is an increase of 102.30% from the latest price.
News
Immunome initiated with an Outperform at William Blair
William Blair initiated coverage of Immunome (IMNM) with an Outperform rating. The company is nearing its first approval with varegacestat, a gamma secretase inhibitor for desmoid tumors, and is build...
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapie...
Immunome initiated with a Hold at Stifel
Stifel analyst Dara Azar initiated coverage of Immunome (IMNM) with a Hold rating and $24 price target Varegacestat’s “debatable differentiation” on efficacy, pain and convenience and second-in-class ...
Immunome announces IND clearance for IM-1340 in solid tumors
Immunome (IMNM) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for IM-1340, a potential first-in-class antibody-drug conjugate for the treatm...
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today ann...
Immunome initiated with a Buy at Alliance Global
Alliance Global initiated coverage of Immunome (IMNM) with a Buy rating and $32 price target Immunome is a biotechnology company focused on developing therapeutics for oncology, the analyst tells inve...
Immunome Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A broad oncology pipeline is advancing, highlighted by a filed NDA for varegacestat targeting desmoid tumors and a robust ADC platform focused on ROR1 and innovative payloads. Strategic emphasis is placed on medical affairs, diagnostic tools, and differentiated clinical outcomes.
Immunome Slides: Corporate presentation
Immunome has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today annou...
Immunome price target raised to $35 from $31 at Wedbush
Wedbush raised the firm’s price target on Immunome (IMNM) to $35 from $31 and keeps an Outperform rating on the shares after the company reported Q2 earnings and provided program…
Immunome reports Q2 EPS (65c), consensus (50c)
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $520.0 million. Immunome (IMNM) expects its current cash position to fund operations into 2028. “We continue to execute…
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome Earnings release: Q2 2026
Immunome released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Immunome Quarterly report: Q2 2026
Immunome has published its Q2 2026 quarterly earnings report on August 11, 2026.
Immunome announces first patient dosed in Phase 1 IM-3050 trial
Immunome (IMNM) announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FA...
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the fir...
Immunome’s NDA for varegacestat in desmoid tumors accepted by FDA
Immunome (IMNM) announced the FDA has accepted its New Drug Application, or NDA, for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, or GSI, for the treatment of adults w...
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Foo...
Immunome announces first patient dosed in Phase 1 trial of IM-1617
Immunome (IMNM) announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and…
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the fir...
Immunome Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by shareholders. No questions were submitted, and voting results will be reported in a Form 8-K filing.
Immunome Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Varegacestat is nearing commercial launch with strong phase III data in desmoid tumors, including rapid pain reduction and a favorable safety profile. The ADC pipeline is advancing, with IM-1021 data expected this year and multiple solid tumor programs progressing. Cash runway extends into 2028, supporting broad development plans.
Immunome announces Ringside trial met primary, secondary endpoints
Immunome (IMNM) announced detailed efficacy and safety results from Ringside, the global, randomized, double-blind, placebo-controlled Phase 3 trial of varegacestat in patients with progressing desmoi...
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced detailed eff...